BridgeBio Pharma (Germany) Analysis
| 2CL Stock | EUR 65.52 1.58 2.47% |
200 Day MA 46.546 | 50 Day MA 63.642 | Beta 1.17 |
BridgeBio Pharma has over 1.4 Billion in debt which may indicate that it relies heavily on debt financing. BridgeBio Pharma's financial risk is the risk to BridgeBio Pharma stockholders that is caused by an increase in debt.
Given that BridgeBio Pharma's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which BridgeBio Pharma is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of BridgeBio Pharma to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, BridgeBio Pharma is said to be less leveraged. If creditors hold a majority of BridgeBio Pharma's assets, the Company is said to be highly leveraged.
BridgeBio Pharma is overvalued with Real Value of 52.96 and Hype Value of 66.39. The main objective of BridgeBio Pharma stock analysis is to determine its intrinsic value, which is an estimate of what BridgeBio Pharma is worth, separate from its market price. There are two main types of BridgeBio Pharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect BridgeBio Pharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of BridgeBio Pharma's stock to identify patterns and trends that may indicate its future price movements.
The BridgeBio Pharma stock is traded in Germany on Frankfurt Exchange, with the market opening at 08:00:00 and closing at 22:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Germany. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and BridgeBio Pharma's ongoing operational relationships across important fundamental and technical indicators.
BridgeBio |
BridgeBio Stock Analysis Notes
About 95.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 3.52. BridgeBio Pharma had not issued any dividends in recent years. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. BRIDGEBIO PHARMA operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 385 people. For more info on BridgeBio Pharma please contact Neil Kumar at 650 391 9740 or go to https://bridgebio.com.BridgeBio Pharma Investment Alerts
| The company reported the revenue of 353.78 M. Net Loss for the year was (495.27 M) with profit before overhead, payroll, taxes, and interest of 338.84 M. | |
| BridgeBio Pharma has accumulated about 837.66 M in cash with (470.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59. | |
| Over 95.0% of the company shares are owned by institutions such as pension funds | |
| Latest headline from news.google.com: Assessing BridgeBio Pharma Valuation After Recent Share Price Volatility - Yahoo Finance |
BridgeBio Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 12.79 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BridgeBio Pharma's market, we take the total number of its shares issued and multiply it by BridgeBio Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.BridgeBio Profitablity
BridgeBio Pharma's profitability indicators refer to fundamental financial ratios that showcase BridgeBio Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, BridgeBio Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, BridgeBio Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of BridgeBio Pharma's profitability requires more research than a typical breakdown of BridgeBio Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.13. Management Efficiency
BridgeBio Pharma has return on total asset (ROA) of (0.4348) % which means that it has lost $0.4348 on every $100 spent on assets. This is way below average. BridgeBio Pharma's management efficiency ratios could be used to measure how well BridgeBio Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Leadership effectiveness at BridgeBio Pharma is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 2nd of February, BridgeBio Pharma shows the Risk Adjusted Performance of 0.151, mean deviation of 1.94, and Downside Deviation of 2.36. BridgeBio Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BridgeBio Pharma mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation to decide if BridgeBio Pharma is priced correctly, providing market reflects its regular price of 65.52 per share.BridgeBio Pharma Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. BridgeBio Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for BridgeBio Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
BridgeBio Pharma Predictive Daily Indicators
BridgeBio Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BridgeBio Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BridgeBio Pharma Forecast Models
BridgeBio Pharma's time-series forecasting models are one of many BridgeBio Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BridgeBio Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.BridgeBio Pharma Debt to Cash Allocation
Many companies such as BridgeBio Pharma, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
BridgeBio Pharma has accumulated 1.4 B in total debt with debt to equity ratio (D/E) of 4.61, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BridgeBio Pharma has a current ratio of 6.76, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BridgeBio Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, BridgeBio Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BridgeBio Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BridgeBio to invest in growth at high rates of return. When we think about BridgeBio Pharma's use of debt, we should always consider it together with cash and equity.BridgeBio Pharma Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the BridgeBio Pharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of BridgeBio Pharma, which in turn will lower the firm's financial flexibility.About BridgeBio Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BridgeBio Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BridgeBio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BridgeBio Pharma. By using and applying BridgeBio Stock analysis, traders can create a robust methodology for identifying BridgeBio entry and exit points for their positions.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. BRIDGEBIO PHARMA operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 385 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding BridgeBio Pharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Complementary Tools for BridgeBio Stock analysis
When running BridgeBio Pharma's price analysis, check to measure BridgeBio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma is operating at the current time. Most of BridgeBio Pharma's value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma's price. Additionally, you may evaluate how the addition of BridgeBio Pharma to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |